{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:29:25Z","timestamp":1747178965070,"version":"3.40.5"},"reference-count":42,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2020,3,3]]},"DOI":"10.1080\/14737167.2020.1744435","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T06:42:46Z","timestamp":1585204966000},"page":"221-228","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis"],"prefix":"10.1080","volume":"20","author":[{"given":"Max","family":"Schlueter","sequence":"first","affiliation":[{"name":"Real World Solutions, IQVIA, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8480-6607","authenticated-orcid":false,"given":"Peter","family":"Rouse","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Pitcher","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peita Louise","family":"Graham-Clarke","sequence":"additional","affiliation":[{"name":"Global Patient Reported Outcomes and Real World Evidence (GPORWE) International, Eli Lilly, West Ryde, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Nicolay","sequence":"additional","affiliation":[{"name":"International Statistics, Lilly Deutschland GmbH, Bad Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid","family":"Fakhouri","sequence":"additional","affiliation":[{"name":"Global Patient Reported Outcomes and Real World Evidence (GPORWE) International, Eli Lilly, Windlesham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,3,25]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30173-8"},{"issue":"7","key":"CIT0002","first-page":"S128","volume":"20","author":"Gibofsky A.","year":"2014","journal-title":"Am J Manag Care"},{"key":"CIT0003","unstructured":"Nomen nescio. The global burden of rheumatoid arthritis will increase. Pharmaceutical Technology [Internet]. 2017 May 26. Available from: https:\/\/www.pharmaceutical-technology.com\/research-reports\/researchreportthe-global-burden-of-rheumatoid-arthritis-will-increase-5825875\/."},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-016-1038-3"},{"volume-title":"The economic burden of rheumatoid arthritis","year":"2010","author":"National Rheumatoid Arthritis Society","key":"CIT0005"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141112"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S35901"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.1.28"},{"issue":"11","key":"CIT0010","first-page":"1245","volume":"84","author":"Wasserman AM","year":"2011","journal-title":"Am Fam Physician"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126532"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken450a"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key054"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.3310\/hta20350"},{"key":"CIT0019","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"Briggs A","year":"2006","edition":"1"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket253"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.3310\/hta15140"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-014-0018-2"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.18203\/2320-6012.ijrms20150329"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.012"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.04.013"},{"key":"CIT0027","unstructured":"Eli L. Data on file: systematic literature review of clinical trials in rheumatoid arthritis. 2016."},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.01.011"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"CIT0030","unstructured":"Dias S, Welton NJ, Sutton AJ, et al. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2014."},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.10.013"},{"key":"CIT0032","unstructured":"Eli L. Data on file: patient HAQ trajectory beyond RA-BEAM study (RA-BEYOND). 2018."},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.12.014"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem115"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110491"},{"key":"CIT0037","unstructured":"Wiles N, Cooper N, Symmons D. Resource use within the Norfolk Arthritis Register (NOAR) Cohort during the first five years of disease: report for Roche (NICE Data on File).\u00a0London: NICE; 2005."},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0327-2"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205013"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.3310\/hta21710"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-14-350"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1002\/art.24169"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-019-0064-9"},{"issue":"2","key":"CIT0044","volume":"78","author":"van de Laar C","year":"2019","journal-title":"BMJ Ann Rheumatic Dis"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2020.1744435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T22:33:22Z","timestamp":1722638002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2020.1744435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3,3]]}},"alternative-id":["10.1080\/14737167.2020.1744435"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2020.1744435","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"type":"print","value":"1473-7167"},{"type":"electronic","value":"1744-8379"}],"subject":[],"published":{"date-parts":[[2020,3,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}